AbbVie Inc $ 87.28 1.05 (1.22%)
Warning! GuruFocus has detected 3 Severe warning signs with ABBV. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for ABBV (AbbVie Inc) from 2012 to Sep 28 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. AbbVie stock (ABBV) PE ratio as of Sep 28 2020 is 18.57. More Details
AbbVie PE Ratio (TTM) Historical Data
View and export this data going back to 2012. Start your Free Trial
AbbVie PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NYSE:LLY NYSE:BMY NYSE:MRK NAS:AMGN NYSE:PFE NAS:GILD NYSE:AGN NAS:BIIB NAS:HZNP OTCPK:GWPRF NYSE:JNJ XSWX:ROG XSWX:NOVN LSE:AZN XPAR:SAN LSE:GSK TSE:4519 XTER:BAYN SHSE:600276 TSE:4568
Traded in other countries ABBV.Austria ABBV34.Brazil ABBV.France 4AB.Germany ABBV.Mexico ABBV.Switzerland 0QCV.UK ABBV.USA
Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a drug company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents over half of the company's current profits. The company was spun off from Abbott in early 2013. The recent announced acquisition of Allergan will add several new drugs in aesthetics and women's health.